Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pre-Eclampsia | 71 | 2023 | 246 | 24.240 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 51 | 2023 | 91 | 13.670 |
Why?
|
Hypertension, Pregnancy-Induced | 19 | 2022 | 69 | 9.860 |
Why?
|
Placenta Growth Factor | 35 | 2022 | 70 | 7.800 |
Why?
|
Pregnancy | 108 | 2023 | 2894 | 7.030 |
Why?
|
Pregnancy Proteins | 18 | 2015 | 38 | 4.490 |
Why?
|
Hypertension | 12 | 2023 | 1141 | 3.930 |
Why?
|
Biomarkers | 38 | 2022 | 1718 | 3.860 |
Why?
|
Premature Birth | 9 | 2023 | 113 | 3.800 |
Why?
|
Placenta | 12 | 2023 | 175 | 3.490 |
Why?
|
Blood Pressure | 14 | 2023 | 1143 | 3.310 |
Why?
|
Angiogenic Proteins | 7 | 2019 | 17 | 2.550 |
Why?
|
Female | 111 | 2023 | 44532 | 2.340 |
Why?
|
Angiogenesis Inducing Agents | 8 | 2022 | 30 | 2.050 |
Why?
|
Pregnancy Outcome | 16 | 2023 | 247 | 1.990 |
Why?
|
Postpartum Period | 9 | 2023 | 135 | 1.850 |
Why?
|
Antihypertensive Agents | 6 | 2021 | 521 | 1.720 |
Why?
|
Pregnancy Trimester, Third | 11 | 2020 | 70 | 1.710 |
Why?
|
Puerperal Disorders | 5 | 2023 | 32 | 1.700 |
Why?
|
Infant, Newborn | 22 | 2023 | 2379 | 1.670 |
Why?
|
Prenatal Care | 5 | 2023 | 72 | 1.660 |
Why?
|
Humans | 111 | 2023 | 86643 | 1.590 |
Why?
|
Prenatal Diagnosis | 3 | 2019 | 104 | 1.570 |
Why?
|
Adult | 64 | 2021 | 25648 | 1.520 |
Why?
|
Pregnancy Complications, Cardiovascular | 5 | 2017 | 104 | 1.330 |
Why?
|
Retrospective Studies | 26 | 2023 | 8489 | 1.310 |
Why?
|
Placentation | 4 | 2020 | 11 | 1.300 |
Why?
|
Receptors, Cell Surface | 9 | 2015 | 286 | 1.290 |
Why?
|
Antigens, CD | 9 | 2015 | 458 | 1.250 |
Why?
|
Postnatal Care | 4 | 2021 | 25 | 1.210 |
Why?
|
Obstetric Labor Complications | 2 | 2021 | 34 | 1.180 |
Why?
|
Peripartum Period | 5 | 2023 | 20 | 1.170 |
Why?
|
Obstetric Labor, Premature | 2 | 2023 | 58 | 1.090 |
Why?
|
Gestational Age | 11 | 2023 | 311 | 1.080 |
Why?
|
Cardiovascular Diseases | 4 | 2021 | 827 | 0.950 |
Why?
|
Vascular Endothelial Growth Factor A | 8 | 2023 | 407 | 0.930 |
Why?
|
Fetal Growth Retardation | 2 | 2021 | 66 | 0.910 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2023 | 105 | 0.890 |
Why?
|
Prospective Studies | 15 | 2023 | 4213 | 0.880 |
Why?
|
Activins | 3 | 2021 | 26 | 0.880 |
Why?
|
Case-Control Studies | 13 | 2021 | 1805 | 0.860 |
Why?
|
Pregnancy Complications | 6 | 2017 | 336 | 0.860 |
Why?
|
Birth Intervals | 1 | 2021 | 7 | 0.800 |
Why?
|
Risk Factors | 19 | 2021 | 5417 | 0.790 |
Why?
|
Furosemide | 1 | 2021 | 33 | 0.790 |
Why?
|
Ventricular Function, Left | 3 | 2021 | 592 | 0.770 |
Why?
|
Practice Patterns, Physicians' | 2 | 2019 | 582 | 0.760 |
Why?
|
Racism | 1 | 2022 | 81 | 0.750 |
Why?
|
Severity of Illness Index | 5 | 2019 | 1801 | 0.740 |
Why?
|
Patient Compliance | 1 | 2021 | 227 | 0.740 |
Why?
|
Trophoblasts | 5 | 2023 | 33 | 0.720 |
Why?
|
Young Adult | 26 | 2021 | 5976 | 0.720 |
Why?
|
Pregnancy Trimester, Second | 8 | 2019 | 66 | 0.700 |
Why?
|
United States | 12 | 2023 | 6672 | 0.690 |
Why?
|
Cardiomyopathies | 5 | 2023 | 240 | 0.690 |
Why?
|
Telemedicine | 1 | 2022 | 169 | 0.680 |
Why?
|
Luteolin | 3 | 2023 | 4 | 0.670 |
Why?
|
Endoglin | 10 | 2017 | 20 | 0.660 |
Why?
|
Heart Ventricles | 3 | 2021 | 760 | 0.650 |
Why?
|
Hydrops Fetalis | 2 | 2020 | 16 | 0.620 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2018 | 318 | 0.600 |
Why?
|
Birth Weight | 5 | 2020 | 145 | 0.600 |
Why?
|
Predictive Value of Tests | 8 | 2021 | 1673 | 0.590 |
Why?
|
Risk Assessment | 6 | 2023 | 2261 | 0.580 |
Why?
|
Tertiary Care Centers | 3 | 2021 | 94 | 0.570 |
Why?
|
Patient Readmission | 4 | 2022 | 329 | 0.570 |
Why?
|
Cohort Studies | 8 | 2023 | 2767 | 0.550 |
Why?
|
Obesity | 2 | 2020 | 963 | 0.540 |
Why?
|
Prevalence | 4 | 2022 | 1239 | 0.540 |
Why?
|
Placental Insufficiency | 1 | 2014 | 4 | 0.510 |
Why?
|
Ouabain | 1 | 2014 | 24 | 0.500 |
Why?
|
HSP27 Heat-Shock Proteins | 1 | 2014 | 33 | 0.500 |
Why?
|
HELLP Syndrome | 2 | 2013 | 8 | 0.490 |
Why?
|
Neovascularization, Physiologic | 4 | 2012 | 133 | 0.490 |
Why?
|
Placenta Diseases | 3 | 2021 | 13 | 0.490 |
Why?
|
Pregnancy Complications, Hematologic | 2 | 2012 | 14 | 0.480 |
Why?
|
Cardiotonic Agents | 1 | 2014 | 87 | 0.480 |
Why?
|
Chicago | 5 | 2021 | 1379 | 0.450 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 151 | 0.450 |
Why?
|
Pregnancy Trimester, First | 4 | 2015 | 63 | 0.450 |
Why?
|
Cesarean Section | 4 | 2019 | 137 | 0.440 |
Why?
|
Prognosis | 7 | 2021 | 3679 | 0.440 |
Why?
|
Pregnancy, Twin | 1 | 2012 | 7 | 0.440 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2012 | 26 | 0.440 |
Why?
|
Fetal Death | 3 | 2020 | 56 | 0.430 |
Why?
|
Maternal Serum Screening Tests | 1 | 2012 | 1 | 0.430 |
Why?
|
Lymphangiogenesis | 1 | 2012 | 38 | 0.430 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2012 | 70 | 0.430 |
Why?
|
Perinatology | 1 | 2012 | 14 | 0.430 |
Why?
|
Eclampsia | 1 | 2012 | 24 | 0.420 |
Why?
|
Pilot Projects | 4 | 2020 | 839 | 0.390 |
Why?
|
Follow-Up Studies | 4 | 2022 | 3640 | 0.380 |
Why?
|
Fetal Diseases | 2 | 2010 | 81 | 0.380 |
Why?
|
Maternal Mortality | 2 | 2022 | 15 | 0.370 |
Why?
|
Infant, Low Birth Weight | 2 | 2020 | 58 | 0.360 |
Why?
|
Cervix Uteri | 1 | 2010 | 65 | 0.360 |
Why?
|
Thrombocytopenia | 1 | 2010 | 183 | 0.340 |
Why?
|
Clinical Competence | 2 | 2012 | 751 | 0.330 |
Why?
|
Vagina | 1 | 2010 | 161 | 0.330 |
Why?
|
Urban Population | 2 | 2019 | 213 | 0.320 |
Why?
|
Epilepsy | 1 | 2012 | 397 | 0.310 |
Why?
|
Ultrasonography, Prenatal | 3 | 2017 | 152 | 0.300 |
Why?
|
Diagnosis, Differential | 5 | 2013 | 1565 | 0.300 |
Why?
|
Cooking | 2 | 2017 | 55 | 0.290 |
Why?
|
Attitude of Health Personnel | 1 | 2012 | 636 | 0.290 |
Why?
|
Haiti | 2 | 2017 | 21 | 0.290 |
Why?
|
Chronic Disease | 2 | 2020 | 971 | 0.290 |
Why?
|
Delivery, Obstetric | 2 | 2023 | 112 | 0.280 |
Why?
|
Cytomegalovirus Infections | 1 | 2007 | 144 | 0.280 |
Why?
|
Angiogenesis Inhibitors | 2 | 2013 | 311 | 0.280 |
Why?
|
Risk | 3 | 2018 | 674 | 0.260 |
Why?
|
Pregnancy in Diabetics | 2 | 2015 | 37 | 0.250 |
Why?
|
Echocardiography | 4 | 2021 | 911 | 0.250 |
Why?
|
Physicians | 1 | 2012 | 673 | 0.250 |
Why?
|
Fallopian Tubes | 1 | 2004 | 41 | 0.240 |
Why?
|
Ovariectomy | 1 | 2004 | 81 | 0.240 |
Why?
|
Length of Stay | 2 | 2018 | 702 | 0.240 |
Why?
|
Carcinoma, Small Cell | 1 | 2004 | 134 | 0.230 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2023 | 83 | 0.230 |
Why?
|
Labor, Obstetric | 1 | 2023 | 46 | 0.220 |
Why?
|
Tissue Culture Techniques | 2 | 2020 | 79 | 0.220 |
Why?
|
Oxidative Stress | 2 | 2019 | 447 | 0.220 |
Why?
|
Perception | 1 | 2023 | 168 | 0.220 |
Why?
|
Diabetes, Gestational | 2 | 2015 | 39 | 0.220 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2023 | 153 | 0.210 |
Why?
|
Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2021 | 2 | 0.210 |
Why?
|
Income | 1 | 2022 | 75 | 0.210 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2023 | 322 | 0.210 |
Why?
|
Stroke Volume | 2 | 2016 | 456 | 0.210 |
Why?
|
Neovascularization, Pathologic | 3 | 2013 | 353 | 0.200 |
Why?
|
Morbidity | 2 | 2019 | 148 | 0.200 |
Why?
|
Aspirin | 2 | 2020 | 156 | 0.200 |
Why?
|
Recurrence | 2 | 2021 | 1139 | 0.200 |
Why?
|
Evidence-Based Practice | 1 | 2021 | 45 | 0.200 |
Why?
|
Cognition | 1 | 2006 | 570 | 0.200 |
Why?
|
Attitude | 1 | 2022 | 127 | 0.200 |
Why?
|
Blood Pressure Determination | 1 | 2021 | 90 | 0.200 |
Why?
|
Uterine Artery | 1 | 2020 | 3 | 0.200 |
Why?
|
Fetofetal Transfusion | 1 | 2020 | 8 | 0.190 |
Why?
|
Reactive Oxygen Species | 1 | 2023 | 480 | 0.190 |
Why?
|
Maternal Health Services | 2 | 2017 | 16 | 0.190 |
Why?
|
Endothelial Cells | 1 | 2023 | 428 | 0.190 |
Why?
|
Time-to-Treatment | 1 | 2021 | 98 | 0.190 |
Why?
|
Endometrium | 1 | 2020 | 48 | 0.190 |
Why?
|
Bronchopulmonary Dysplasia | 1 | 2020 | 39 | 0.190 |
Why?
|
Vasodilation | 1 | 2020 | 96 | 0.190 |
Why?
|
Membrane Proteins | 3 | 2013 | 1196 | 0.190 |
Why?
|
India | 1 | 2020 | 120 | 0.190 |
Why?
|
Fibrin | 1 | 2020 | 84 | 0.190 |
Why?
|
NF-kappa B | 1 | 2023 | 444 | 0.190 |
Why?
|
Betamethasone | 1 | 2019 | 5 | 0.180 |
Why?
|
Fetal Organ Maturity | 1 | 2019 | 4 | 0.180 |
Why?
|
Organoids | 1 | 2020 | 61 | 0.180 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2023 | 683 | 0.180 |
Why?
|
Urban Health | 1 | 2020 | 55 | 0.180 |
Why?
|
Myocardial Contraction | 1 | 2021 | 244 | 0.180 |
Why?
|
Myxoma | 1 | 2019 | 28 | 0.180 |
Why?
|
Health Care Costs | 1 | 2021 | 238 | 0.180 |
Why?
|
Drug Utilization | 1 | 2019 | 65 | 0.170 |
Why?
|
Health Personnel | 1 | 2021 | 202 | 0.170 |
Why?
|
Health Status Disparities | 1 | 2021 | 170 | 0.170 |
Why?
|
Heart Neoplasms | 1 | 2019 | 62 | 0.170 |
Why?
|
Poverty | 1 | 2020 | 173 | 0.170 |
Why?
|
Cost-Benefit Analysis | 1 | 2021 | 454 | 0.170 |
Why?
|
Medical Records | 1 | 2019 | 119 | 0.170 |
Why?
|
Time Factors | 4 | 2021 | 5210 | 0.170 |
Why?
|
China | 1 | 2019 | 228 | 0.170 |
Why?
|
Odds Ratio | 1 | 2020 | 678 | 0.170 |
Why?
|
Patient Education as Topic | 1 | 2021 | 351 | 0.160 |
Why?
|
Heart Diseases | 1 | 2021 | 290 | 0.160 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2019 | 179 | 0.160 |
Why?
|
Inflammation | 1 | 2023 | 920 | 0.160 |
Why?
|
Infant, Premature | 1 | 2020 | 290 | 0.160 |
Why?
|
Up-Regulation | 1 | 2020 | 712 | 0.160 |
Why?
|
Immunoassay | 1 | 2018 | 92 | 0.150 |
Why?
|
Quality Improvement | 1 | 2021 | 428 | 0.150 |
Why?
|
Parity | 3 | 2013 | 93 | 0.150 |
Why?
|
Ovarian Neoplasms | 1 | 2004 | 744 | 0.150 |
Why?
|
Triage | 1 | 2018 | 108 | 0.150 |
Why?
|
Healthcare Disparities | 1 | 2022 | 371 | 0.150 |
Why?
|
Glucocorticoids | 1 | 2019 | 352 | 0.150 |
Why?
|
Maternal Death | 1 | 2017 | 3 | 0.150 |
Why?
|
Maternal Exposure | 1 | 2017 | 57 | 0.150 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 376 | 0.150 |
Why?
|
Air Pollution, Indoor | 1 | 2017 | 63 | 0.150 |
Why?
|
Gelsolin | 1 | 2016 | 11 | 0.150 |
Why?
|
Rural Population | 1 | 2017 | 136 | 0.140 |
Why?
|
Chorionic Villi | 1 | 2016 | 11 | 0.140 |
Why?
|
Heart | 2 | 2017 | 539 | 0.140 |
Why?
|
Relaxin | 1 | 2016 | 8 | 0.140 |
Why?
|
Transcriptome | 1 | 2020 | 580 | 0.140 |
Why?
|
Air Pollution | 1 | 2017 | 68 | 0.140 |
Why?
|
Body Mass Index | 1 | 2019 | 770 | 0.140 |
Why?
|
Prolactin | 1 | 2016 | 88 | 0.140 |
Why?
|
Rats, Sprague-Dawley | 2 | 2020 | 1219 | 0.140 |
Why?
|
Shock, Cardiogenic | 1 | 2016 | 95 | 0.140 |
Why?
|
Pandemics | 1 | 2022 | 740 | 0.130 |
Why?
|
Antiphospholipid Syndrome | 1 | 2015 | 20 | 0.130 |
Why?
|
Extracellular Vesicles | 1 | 2016 | 42 | 0.130 |
Why?
|
Survival Rate | 1 | 2019 | 1863 | 0.130 |
Why?
|
Cardenolides | 1 | 2014 | 1 | 0.130 |
Why?
|
Digitoxin | 1 | 2014 | 3 | 0.130 |
Why?
|
Infant | 1 | 2021 | 3046 | 0.120 |
Why?
|
Animals | 5 | 2020 | 26582 | 0.120 |
Why?
|
Hospitalization | 1 | 2020 | 849 | 0.120 |
Why?
|
Recombinant Proteins | 1 | 2016 | 1014 | 0.120 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 2438 | 0.120 |
Why?
|
Infant, Small for Gestational Age | 2 | 2011 | 28 | 0.120 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2015 | 206 | 0.120 |
Why?
|
Fetal Macrosomia | 2 | 2011 | 10 | 0.120 |
Why?
|
Lung | 1 | 2019 | 1170 | 0.120 |
Why?
|
Boston | 1 | 2013 | 33 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 2 | 2012 | 860 | 0.110 |
Why?
|
Sensitivity and Specificity | 2 | 2016 | 1991 | 0.110 |
Why?
|
Adolescent | 7 | 2018 | 8981 | 0.110 |
Why?
|
ROC Curve | 2 | 2012 | 752 | 0.110 |
Why?
|
Mitochondria | 1 | 2016 | 535 | 0.110 |
Why?
|
Rats | 2 | 2020 | 3990 | 0.110 |
Why?
|
Hypoxia | 1 | 2017 | 641 | 0.110 |
Why?
|
Aneuploidy | 1 | 2012 | 55 | 0.110 |
Why?
|
Pulmonary Edema | 1 | 2012 | 50 | 0.110 |
Why?
|
Cell-Derived Microparticles | 1 | 2012 | 11 | 0.100 |
Why?
|
Neural Tube Defects | 1 | 2012 | 43 | 0.100 |
Why?
|
Directive Counseling | 1 | 2012 | 34 | 0.100 |
Why?
|
Systole | 1 | 2012 | 129 | 0.100 |
Why?
|
Cells, Cultured | 2 | 2014 | 2818 | 0.100 |
Why?
|
Phosphorylation | 1 | 2014 | 1106 | 0.100 |
Why?
|
Health Care Surveys | 1 | 2012 | 278 | 0.100 |
Why?
|
RNA, Messenger | 2 | 2014 | 1981 | 0.100 |
Why?
|
Chromosome Disorders | 1 | 2011 | 114 | 0.100 |
Why?
|
Vitamin D-Binding Protein | 1 | 2010 | 7 | 0.100 |
Why?
|
Treatment Outcome | 2 | 2020 | 7993 | 0.090 |
Why?
|
Dietary Supplements | 1 | 2011 | 128 | 0.090 |
Why?
|
Rupture, Spontaneous | 1 | 2010 | 43 | 0.090 |
Why?
|
Logistic Models | 2 | 2012 | 1186 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 1961 | 0.090 |
Why?
|
Antioxidants | 1 | 2011 | 223 | 0.090 |
Why?
|
fas Receptor | 1 | 2010 | 75 | 0.090 |
Why?
|
Life Style | 1 | 2010 | 189 | 0.090 |
Why?
|
Gynecology | 1 | 2011 | 124 | 0.090 |
Why?
|
Heart Failure | 1 | 2018 | 1204 | 0.090 |
Why?
|
Twins | 1 | 2009 | 65 | 0.090 |
Why?
|
Obstetrics | 1 | 2011 | 120 | 0.080 |
Why?
|
Abruptio Placentae | 1 | 2008 | 13 | 0.080 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2013 | 350 | 0.080 |
Why?
|
Image Enhancement | 1 | 2012 | 563 | 0.080 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2010 | 302 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2012 | 295 | 0.080 |
Why?
|
Databases, Factual | 3 | 2018 | 814 | 0.080 |
Why?
|
Vitamin D | 1 | 2010 | 261 | 0.080 |
Why?
|
Internal Medicine | 1 | 2011 | 347 | 0.070 |
Why?
|
Nigeria | 2 | 2017 | 152 | 0.070 |
Why?
|
Cross-Sectional Studies | 1 | 2012 | 1621 | 0.070 |
Why?
|
Smoking | 1 | 2010 | 609 | 0.070 |
Why?
|
Tocolytic Agents | 1 | 2006 | 8 | 0.070 |
Why?
|
Magnesium Sulfate | 1 | 2006 | 15 | 0.070 |
Why?
|
Male | 5 | 2022 | 40965 | 0.070 |
Why?
|
Syndrome | 1 | 2007 | 446 | 0.070 |
Why?
|
Proteinuria | 2 | 2021 | 107 | 0.070 |
Why?
|
Fetal Weight | 1 | 2005 | 15 | 0.070 |
Why?
|
Diabetes Complications | 1 | 2007 | 207 | 0.070 |
Why?
|
Cheek | 1 | 2005 | 22 | 0.070 |
Why?
|
Postoperative Complications | 1 | 2015 | 2207 | 0.070 |
Why?
|
Ethanol | 2 | 2017 | 249 | 0.060 |
Why?
|
Renal Dialysis | 1 | 2008 | 355 | 0.060 |
Why?
|
Vinblastine | 1 | 2004 | 108 | 0.060 |
Why?
|
Bleomycin | 1 | 2004 | 98 | 0.060 |
Why?
|
Surveys and Questionnaires | 1 | 2012 | 2501 | 0.060 |
Why?
|
Memory | 1 | 2006 | 225 | 0.060 |
Why?
|
Etoposide | 1 | 2004 | 196 | 0.060 |
Why?
|
Cyclophosphamide | 1 | 2004 | 299 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2006 | 999 | 0.060 |
Why?
|
Doxorubicin | 1 | 2004 | 295 | 0.060 |
Why?
|
Signal Transduction | 1 | 2013 | 3241 | 0.060 |
Why?
|
Cisplatin | 1 | 2004 | 612 | 0.050 |
Why?
|
Gravidity | 1 | 2021 | 7 | 0.050 |
Why?
|
Attention | 1 | 2006 | 388 | 0.050 |
Why?
|
American Heart Association | 1 | 2021 | 92 | 0.050 |
Why?
|
B7-H1 Antigen | 1 | 2023 | 250 | 0.050 |
Why?
|
T-Lymphocyte Subsets | 1 | 2023 | 272 | 0.050 |
Why?
|
Decidua | 1 | 2020 | 19 | 0.050 |
Why?
|
Follistatin-Related Proteins | 1 | 2020 | 6 | 0.050 |
Why?
|
Follistatin | 1 | 2020 | 7 | 0.050 |
Why?
|
Combined Modality Therapy | 1 | 2004 | 1686 | 0.050 |
Why?
|
Consensus | 1 | 2021 | 335 | 0.050 |
Why?
|
Stromal Cells | 1 | 2020 | 143 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 1 | 2010 | 2601 | 0.040 |
Why?
|
Aorta | 1 | 2020 | 280 | 0.040 |
Why?
|
Algorithms | 1 | 2007 | 1830 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2018 | 2705 | 0.040 |
Why?
|
Incidence | 2 | 2016 | 1577 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2004 | 1939 | 0.040 |
Why?
|
Down-Regulation | 1 | 2020 | 504 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 916 | 0.040 |
Why?
|
Exercise | 1 | 2021 | 315 | 0.040 |
Why?
|
Limit of Detection | 1 | 2018 | 20 | 0.040 |
Why?
|
Automation, Laboratory | 1 | 2018 | 10 | 0.040 |
Why?
|
Heart Atria | 1 | 2019 | 250 | 0.040 |
Why?
|
Chromatin | 1 | 2020 | 380 | 0.040 |
Why?
|
Societies, Medical | 1 | 2021 | 572 | 0.040 |
Why?
|
Perinatal Care | 1 | 2017 | 18 | 0.040 |
Why?
|
Fetal Blood | 1 | 2017 | 90 | 0.040 |
Why?
|
Equipment Design | 1 | 2018 | 406 | 0.040 |
Why?
|
Electron Transport Complex IV | 1 | 2016 | 47 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2018 | 349 | 0.040 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2015 | 10 | 0.030 |
Why?
|
Pregnancy, High-Risk | 1 | 2015 | 16 | 0.030 |
Why?
|
Microscopy, Electron | 1 | 2016 | 503 | 0.030 |
Why?
|
Comorbidity | 1 | 2018 | 943 | 0.030 |
Why?
|
Heparin | 1 | 2015 | 175 | 0.030 |
Why?
|
Phenotype | 1 | 2021 | 2378 | 0.030 |
Why?
|
Recovery of Function | 1 | 2016 | 272 | 0.030 |
Why?
|
Survival Analysis | 1 | 2017 | 1538 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 243 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 1621 | 0.030 |
Why?
|
Bromocriptine | 1 | 2012 | 12 | 0.030 |
Why?
|
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2012 | 16 | 0.030 |
Why?
|
Anticoagulants | 1 | 2015 | 408 | 0.030 |
Why?
|
Middle Aged | 3 | 2017 | 25028 | 0.030 |
Why?
|
Organ Culture Techniques | 1 | 2012 | 135 | 0.030 |
Why?
|
Trisomy 13 Syndrome | 1 | 2011 | 1 | 0.030 |
Why?
|
Ascorbic Acid | 1 | 2011 | 37 | 0.030 |
Why?
|
Lipid Peroxidation | 1 | 2011 | 44 | 0.030 |
Why?
|
Vitamin E | 1 | 2011 | 35 | 0.030 |
Why?
|
Free Radicals | 1 | 2011 | 73 | 0.020 |
Why?
|
Trisomy | 1 | 2011 | 55 | 0.020 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2011 | 51 | 0.020 |
Why?
|
Pregnancy, Ectopic | 1 | 2011 | 36 | 0.020 |
Why?
|
Endoplasmic Reticulum Stress | 1 | 2011 | 83 | 0.020 |
Why?
|
Anthropometry | 1 | 2010 | 74 | 0.020 |
Why?
|
Myocytes, Cardiac | 1 | 2012 | 275 | 0.020 |
Why?
|
Trans-Activators | 1 | 2012 | 429 | 0.020 |
Why?
|
Massachusetts | 1 | 2009 | 33 | 0.020 |
Why?
|
Pregnancy, Multiple | 1 | 2009 | 37 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2013 | 567 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2010 | 912 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2010 | 567 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2012 | 1924 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2011 | 865 | 0.020 |
Why?
|
Creatinine | 1 | 2007 | 338 | 0.020 |
Why?
|
Dystocia | 1 | 2005 | 2 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2012 | 2232 | 0.020 |
Why?
|
Transcription Factors | 1 | 2012 | 1565 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2005 | 364 | 0.020 |
Why?
|
Age Factors | 1 | 2009 | 1851 | 0.020 |
Why?
|
Probability | 1 | 2005 | 355 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2013 | 1373 | 0.020 |
Why?
|
Child | 1 | 2012 | 6927 | 0.010 |
Why?
|
Mice | 1 | 2012 | 11352 | 0.010 |
Why?
|